{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T02:58:00Z","timestamp":1784602680873,"version":"3.55.0"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Pharmacology"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.coph.2017.10.015","type":"journal-article","created":{"date-parts":[[2017,11,22]],"date-time":"2017-11-22T21:02:10Z","timestamp":1511384530000},"page":"158-166","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"special_numbering":"C","title":["Existing and emerging therapies for managing constipation and diarrhea"],"prefix":"10.1016","volume":"37","author":[{"given":"Adil E","family":"Bharucha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mira M","family":"Wouters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Tack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coph.2017.10.015_bib0305","first-page":"578","article-title":"Peripheral mechanisms in irritable bowel syndrome","volume":"368","author":"Camilleri","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2017.10.015_bib0310","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1053\/j.gastro.2012.10.028","article-title":"AGA practice guideline on constipation: technical review","volume":"144","author":"Bharucha","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coph.2017.10.015_bib0315","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/s11894-015-0473-x","article-title":"New and investigational agents for irritable bowel syndrome","volume":"17","author":"Wadhwa","year":"2015","journal-title":"Curr Gastroenterol Rep"},{"key":"10.1016\/j.coph.2017.10.015_bib0320","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1053\/j.gastro.2010.01.022","article-title":"Taking a lesson from microbial diarrheagenesis in the management of chronic constipation","volume":"138","author":"Bharucha","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coph.2017.10.015_bib0325","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1007\/s10620-013-2953-x","article-title":"Clarification of linaclotide pharmacology presented in a recent clinical study of plecanatide","volume":"59","author":"Busby","year":"2014","journal-title":"Digest Dis Sci"},{"key":"10.1016\/j.coph.2017.10.015_bib0330","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/j.1365-2036.2012.05011.x","article-title":"Systematic review: cardiovascular safety profile of 5-HT(4) agonists developed for gastrointestinal disorders","volume":"35","author":"Tack","year":"2012","journal-title":"Aliment Pharmacol Therap"},{"key":"10.1016\/j.coph.2017.10.015_bib0335","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/nmo.12217","article-title":"Effect of prucalopride on symptoms of chronic constipation","volume":"26","author":"Tack","year":"2014","journal-title":"Neurogastroenterol Motil"},{"key":"10.1016\/j.coph.2017.10.015_bib0340","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1038\/ajg.2011.162","article-title":"A randomized placebo-controlled phase IIb trial of a3309, a bile acid transporter inhibitor, for chronic idiopathic constipation [Erratum appears in Am J Gastroenterol. 2014 May;109(5):782]","volume":"106","author":"Chey","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.coph.2017.10.015_bib0345","series-title":"Ardelyx Reports Successful Phase 3 T3MPO-1 Trial of Tenapanor in Patients with IBS-C: Study Achieves Primary Endpoint; Tenapanor Well-tolerated in Treated patients","author":"Ardelyx","year":"2017"},{"key":"10.1016\/j.coph.2017.10.015_sbref0350","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/ajg.2017.41","article-title":"Tenapanor treatment of patients with constipation-predominant irritable bowel syndrome: a phase 2, randomized, placebo-controlled efficacy and safety trial","volume":"112","author":"Chey","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.coph.2017.10.015_sbref0355","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/2327-6924.12387","article-title":"Diarrhea-predominant irritable bowel syndrome: diagnosis, etiology, and new treatment considerations","volume":"28","author":"Lacy","year":"2016","journal-title":"J Am Assoc Nurse Pract"},{"key":"10.1016\/j.coph.2017.10.015_bib0360","first-page":"14","article-title":"FODMAPs alter symptoms and the metabolome of patients with IBS: a randomised controlled trial","volume":"14","author":"McIntosh","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.coph.2017.10.015_bib0365","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3109\/00365521.2015.1063156","article-title":"Does oral alpha-galactosidase relieve irritable bowel symptoms?","volume":"51","author":"Hillila","year":"2016","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.coph.2017.10.015_bib0370","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1053\/cgh.2003.50019","article-title":"A randomized, controlled exploratory study of clonidine in diarrhea-predominant irritable bowel syndrome","volume":"1","author":"Camilleri","year":"2003","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.coph.2017.10.015_bib0375","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.cgh.2013.06.035","article-title":"Effects of clonidine in women with fecal incontinence","volume":"12","author":"Bharucha","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.coph.2017.10.015_bib0380","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1056\/NEJMoa1505180","article-title":"Eluxadoline for irritable bowel syndrome with diarrhea","volume":"374","author":"Lembo","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2017.10.015_bib0385","first-page":"18","article-title":"Eluxadoline efficacy in IBS-D patients who report prior loperamide use","volume":"18","author":"Lacy","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.coph.2017.10.015_bib0390","series-title":"FDA Drug Safety Communication: FDA Warns About Increased Risk of Serious Pancreatitis With Irritable Bowel Drug Viberzi (Eluxadoline) in Patients Without a Gallbladder","author":"Administration USFaD","year":"2017"},{"key":"10.1016\/j.coph.2017.10.015_bib0395","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1004409","article-title":"Rifaximin therapy for patients with irritable bowel syndrome without constipation","volume":"364","author":"Pimentel","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2017.10.015_sbref0400","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1097\/MOG.0000000000000348","article-title":"Small intestinal bacterial overgrowth as a cause for irritable bowel syndrome: guilty or not guilty?","volume":"33","author":"Aziz","year":"2017","journal-title":"Curr Opin Gastroenterol"},{"key":"10.1016\/j.coph.2017.10.015_bib0405","series-title":"Rifamycin SV-MMX\u00ae 600mg Tablets Administered Three or Two Times Daily to Patients With IBS-D","author":"Cosmo Technologies","year":"2017"},{"key":"10.1016\/j.coph.2017.10.015_bib0410","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1038\/ajg.2009.223","article-title":"Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis","volume":"104","author":"Ford","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.coph.2017.10.015_bib0415","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1038\/ajg.2010.25","article-title":"Ischemic colitis and complications of constipation associated with the use of alosetron under a risk management plan: clinical characteristics, outcomes, and incidences","volume":"105","author":"Chang","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.coph.2017.10.015_bib0420","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.cgh.2013.11.024","article-title":"Effect of ramosetron on stool consistency in male patients with irritable bowel syndrome with diarrhea","volume":"12","author":"Fukudo","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.coph.2017.10.015_sbref0425","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1053\/j.gastro.2015.10.047","article-title":"Ramosetron reduces symptoms of irritable bowel syndrome with diarrhea and improves quality of life in women","volume":"150","author":"Fukudo","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coph.2017.10.015_bib0430","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.cgh.2009.10.020","article-title":"Effects of chenodeoxycholate and a bile acid sequestrant, colesevelam, on intestinal transit and bowel function","volume":"8","author":"Odunsi-Shiyanbade","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.coph.2017.10.015_sbref0435","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/apt.13065","article-title":"Effect of colesevelam on faecal bile acids and bowel functions in diarrhoea-predominant irritable bowel syndrome","volume":"41","author":"Camilleri","year":"2015","journal-title":"Aliment Pharmacol Therap"},{"key":"10.1016\/j.coph.2017.10.015_sbref0440","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1136\/gutjnl-2013-305965","article-title":"Increased colonic bile acid exposure: a relevant factor for symptoms and treatment in IBS","volume":"64","author":"Bajor","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.coph.2017.10.015_bib0445","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/apt.12999","article-title":"The response of patients with bile acid diarrhoea to the farnesoid X receptor agonist obeticholic acid","volume":"41","author":"Walters","year":"2015","journal-title":"Aliment Pharmacol Therap"},{"key":"10.1016\/j.coph.2017.10.015_bib0450","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1111\/nmo.12616","article-title":"Targeting tachykinin receptors for the treatment of functional gastrointestinal disorders with a focus on irritable bowel syndrome","volume":"27","author":"Corsetti","year":"2015","journal-title":"Neurogastroenterol Motil"},{"key":"10.1016\/j.coph.2017.10.015_sbref0455","first-page":"15","article-title":"The neurokinin-2 receptor antagonist ibodutant improves overall symptoms, abdominal pain and stool pattern in female patients in a phase II study of diarrhoea-predominant IBS","volume":"15","author":"Tack","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.coph.2017.10.015_bib0460","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.neuropharm.2015.07.011","article-title":"Anti-stress effects of ONO-2952, a novel translocator protein 18 kDa antagonist, in rats","volume":"99","author":"Mitsui","year":"2015","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.coph.2017.10.015_sbref0465","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/apt.13839","article-title":"Randomised clinical trial: exploratory phase 2 study of ONO-2952 in diarrhoea-predominant irritable bowel syndrome","volume":"45","author":"Whitehead","year":"2017","journal-title":"Aliment Pharmacol Therap"},{"key":"10.1016\/j.coph.2017.10.015_bib0470","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1016\/j.clinthera.2016.06.012","article-title":"Lanreotide autogel in the treatment of idiopathic refractory diarrhea: results of an exploratory, controlled, before and after, open-label, multicenter, prospective clinical trial","volume":"38","author":"Bisschops","year":"2016","journal-title":"Clin Therap"},{"key":"10.1016\/j.coph.2017.10.015_sbref0475","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1053\/j.gastro.2015.12.034","article-title":"Histamine receptor H1-mediated sensitization of TRPV1 mediates visceral hypersensitivity and symptoms in patients with irritable bowel syndrome","volume":"150","author":"Wouters","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coph.2017.10.015_bib0480","doi-asserted-by":"crossref","first-page":"S102","DOI":"10.1016\/S0016-5085(17)30683-2","article-title":"434 \u2013 Evidence for TRP channel sensitization in IBS with histamine 1 receptor antagonism as effective treatment","volume":"152","author":"Balemans","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coph.2017.10.015_bib0485","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1080\/00365520500206442","article-title":"A combination of peppermint oil and caraway oil attenuates the post-inflammatory visceral hyperalgesia in a rat model","volume":"41","author":"Adam","year":"2006","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.coph.2017.10.015_bib0490","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1007\/s10620-015-3858-7","article-title":"A novel delivery system of peppermint oil is an effective therapy for irritable bowel syndrome symptoms","volume":"61","author":"Cash","year":"2016","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.coph.2017.10.015_bib0495","doi-asserted-by":"crossref","DOI":"10.1111\/j.1365-2982.2009.01310.x","article-title":"Protease-activated receptor-4 (PAR 4): a role as inhibitor of visceral pain and hypersensitivity","volume":"21","author":"Aug\u00e9","year":"2009","journal-title":"Neurogastroenterol Motil"},{"key":"10.1016\/j.coph.2017.10.015_bib0500","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1172\/JCI29255","article-title":"Role for protease activity in visceral pain in irritable bowel syndrome","volume":"117","author":"Cenac","year":"2007","journal-title":"J Clin Invest"},{"key":"10.1016\/j.coph.2017.10.015_bib0505","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1136\/gutjnl-2016-312094","article-title":"Epithelial expression and function of trypsin-3 in irritable bowel syndrome","volume":"66","author":"Rolland-Fourcade","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.coph.2017.10.015_bib0510","first-page":"42","article-title":"Case report of irritable bowel syndrome responding to omalizumab","author":"Magen","year":"2015","journal-title":"Georgian Med News"},{"key":"10.1016\/j.coph.2017.10.015_bib0515","doi-asserted-by":"crossref","first-page":"9451","DOI":"10.3748\/wjg.v22.i43.9451","article-title":"Possible therapeutic role of IgE blockade in irritable bowel syndrome","volume":"22","author":"Magen","year":"2016","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.coph.2017.10.015_bib0520","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1177\/1756283X15588875","article-title":"Immunoglobulin E in irritable bowel syndrome: another target for treatment?. A case report and literature review","volume":"8","author":"Pearson","year":"2015","journal-title":"Therap Adv Gastroenterol"},{"key":"10.1016\/j.coph.2017.10.015_bib0525","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1136\/gutjnl-2013-306236","article-title":"Increased humoral immunity in the jejunum of diarrhoea-predominant irritable bowel syndrome associated with clinical manifestations","volume":"64","author":"Vicario","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.coph.2017.10.015_bib0530","first-page":"5","article-title":"Potential mechanisms of effects of serum-derived bovine immunoglobulin\/protein isolate therapy in patients with diarrhea-predominant irritable bowel syndrome","author":"Valentin","year":"2017","journal-title":"Physiol Rep"},{"key":"10.1016\/j.coph.2017.10.015_bib0535","doi-asserted-by":"crossref","first-page":"e0120278","DOI":"10.1371\/journal.pone.0120278","article-title":"Bovine immunoglobulin\/protein isolate binds pro-inflammatory bacterial compounds and prevents immune activation in an intestinal co-culture model","volume":"10","author":"Detzel","year":"2015","journal-title":"PLOS ONE"},{"key":"10.1016\/j.coph.2017.10.015_sbref0540","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1111\/apt.13958","article-title":"Randomised clinical trial: the analgesic properties of dietary supplementation with palmitoylethanolamide and polydatin in irritable bowel syndrome","volume":"45","author":"Cremon","year":"2017","journal-title":"Aliment Pharmacol Therap"},{"key":"10.1016\/j.coph.2017.10.015_bib0545","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1111\/nmo.12577","article-title":"Enteric glial cells are associated with stress-induced colonic hyper-contraction in maternally separated rats [Erratum appears in Neurogastroenterol Motil. 2016 Feb;28(2):306; PMID: 26806098]","volume":"27","author":"Fujikawa","year":"2015","journal-title":"Neurogastroenterol Motil"},{"key":"10.1016\/j.coph.2017.10.015_bib0550","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1053\/j.gastro.2013.09.030","article-title":"Postoperative ileus involves interleukin-1 receptor signaling in enteric glia","volume":"146","author":"Stoffels","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coph.2017.10.015_bib0555","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1136\/gutjnl-2013-305005","article-title":"Palmitoylethanolamide improves colon inflammation through an enteric glia\/toll like receptor 4-dependent PPAR-alpha activation","volume":"63","author":"Esposito","year":"2014","journal-title":"Gut"},{"key":"10.1016\/j.coph.2017.10.015_sbref0560","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1111\/nmo.12851","article-title":"Effect of vitamin D on gastrointestinal symptoms and health-related quality of life in irritable bowel syndrome patients: a randomized double-blind clinical trial","volume":"28","author":"Abbasnezhad","year":"2016","journal-title":"Neurogastroenterol Motil"},{"key":"10.1016\/j.coph.2017.10.015_bib0565","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/S0025-6196(12)60797-6","article-title":"Selective 5-hydroxytryptamine type 3 receptor antagonism with ondansetron as treatment for diarrhea-predominant irritable bowel syndrome: a pilot study","volume":"67","author":"Steadman","year":"1992","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.coph.2017.10.015_bib0570","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1016\/0016-5085(94)90008-6","article-title":"A 5HT3 antagonist corrects the postprandial colonic hypertonic response in carcinoid diarrhea","volume":"106","author":"von der Ohe","year":"1994","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coph.2017.10.015_bib0575","doi-asserted-by":"crossref","first-page":"e0172846","DOI":"10.1371\/journal.pone.0172846","article-title":"Efficacy and safety of 5-hydroxytryptamine 3 receptor antagonists in irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials","volume":"12","author":"Zheng","year":"2017","journal-title":"PLOS ONE"},{"key":"10.1016\/j.coph.2017.10.015_bib0580","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.pharep.2016.12.001","article-title":"Methyl-orvinol-dual activity opioid receptor ligand inhibits gastrointestinal transit and alleviates abdominal pain in the mouse models mimicking diarrhea-predominant irritable bowel syndrome","volume":"69","author":"Zieli\u0144ska","year":"2017","journal-title":"Pharmacol Rep"},{"key":"10.1016\/j.coph.2017.10.015_bib0585","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1111\/apt.13958","article-title":"Randomised clinical trial: the analgesic properties of dietary supplementation with palmitoylethanolamide and polydatin in irritable bowel syndrome","volume":"45","author":"Cremon","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.coph.2017.10.015_bib0590","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1136\/gutjnl-2013-305870","article-title":"Histamine H4 and H1 receptors contribute to postinflammatory visceral hypersensitivity","volume":"63","author":"Deiteren","year":"2014","journal-title":"Gut"},{"key":"10.1016\/j.coph.2017.10.015_bib0595","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.pain.2009.04.017","article-title":"Fecal proteases from diarrheic-IBS and ulcerative colitis patients exert opposite effect on visceral sensitivity in mice","volume":"144","author":"Annah\u00e1zi","year":"2009","journal-title":"Pain"},{"key":"10.1016\/j.coph.2017.10.015_bib0600","doi-asserted-by":"crossref","DOI":"10.1111\/nmo.13025","article-title":"G protein-coupled estrogen receptor and estrogen receptor ligands regulate colonic motility and visceral pain","author":"Zieli\u0144ska","year":"2017","journal-title":"Neurogastroenterol Motil"}],"container-title":["Current Opinion in Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489217301042?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489217301042?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,8,8]],"date-time":"2022-08-08T02:14:41Z","timestamp":1659924881000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471489217301042"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":60,"alternative-id":["S1471489217301042"],"URL":"https:\/\/doi.org\/10.1016\/j.coph.2017.10.015","relation":{},"ISSN":["1471-4892"],"issn-type":[{"value":"1471-4892","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Existing and emerging therapies for managing constipation and diarrhea","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coph.2017.10.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}